"Rising cases of Covid-19 belong to sub lineage of Omicron virus": CEO, Dangs Lab
Dr. Dangs Lab
, Arjun Dang on Tuesday stated that the rising cases of Covid-19 belonged to the sub-lineage of the Omicron virus.
Dang further stated that in states like Tamil Nadu and Gujarat, the variants that were named as 'Variants under Monitoring' were of types LF7 and NV181 and were more transmissible.
"We must understand that the current spreading variants are again a sublineage of the Omicron virus. Additionally, in states like Tamil Nadu and Gujarat, we have certain other sub-variants that have been named Variants Under Monitoring, and these are basically of two types, LF7 and NV181. Currently, the cases that we are seeing are more transmissible.
They can infect people easily, but again, from the severity perspective, till now, we have not seen any severe cases," Dang told ANI.
He further stated that symptoms of patients were only common cold and flu, and added that hospitalisations currently were minimal.
"All of these are actually presenting as common cold and flu, and the usual symptoms that we have in any kind of common cold, even the hospitalisations, have been minimal," he added.
The CEO further stated that the hospital and staff were better prepared, informed and had better surveillance tools, further stating that the country was in a good place from the preparedness perspective to face the situation effectively.
"There has been an increase in the number of sample requests that we are receiving. But this time, we are better prepared, more informed, and we have better surveillance tools.
With the scientific tests that we have, we are in a good place from the preparedness perspective to face this effectively and minimise any kind of damage that the current wave might cause," he added.
Meanwhile, on May 26, the Indian Council of Medical Research (ICMR) also confirmed that while Covid-19 cases were reported again in parts of the country, current variants in circulation were showing mild symptoms similar to the Omicron strain.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
43 minutes ago
- News18
Worlds first human spinal cord implant to take place in Israel
Tel Aviv [Israel], August 20 (ANI/TPS): Israel is preparing to perform the world's first-ever human spinal cord implant using a patient's own cells, a medical breakthrough that could allow paralysed patients to stand and walk again, Tel Aviv University announced on surgery, expected in the coming months, will take place in Israel and marks a historic milestone in regenerative to the World Health Organisation, over 15 million people worldwide are living with spinal cord injuries, with the majority resulting from traumatic causes such as falls, road traffic accidents, and spinal cord injuries cannot be fully cured, so treatment focuses on stabilising the patient, preventing further damage, and maximising function. Emergency care often involves immobilising the spine, reducing inflammation, and sometimes performing surgery to repair fractures or relieve pressure. Rehabilitation includes physical and occupational therapy, as well as assistive devices like wheelchairs and braces. While experimental therapies–including stem cells and robotic devices–are being explored, no treatment yet reliably restores full spinal cord cord injuries are one of the few human injuries where the body cannot naturally heal itself, and the tissue is both structurally complex and extremely sensitive.'The spinal cord transmits electrical signals from the brain to all parts of the body. When it is severed by trauma such as a car accident, a fall, or a combat injury, the chain is broken. Think of an electrical cable that has been cut: when the two ends no longer touch, the signal cannot pass, and the patient remains paralysed below the injury," explained Professor Tal Dvir, head of the Sagol Centre for Regenerative Biotechnology and the Nanotechnology Centre at Tel Aviv University, who is leading the effort. Dvir is also the chief scientist at Matricelf, the Israeli biotech company commercialising the other tissues, spinal cord neurons cannot naturally regenerate, and over time, scar tissue blocks remaining signals. The new procedure aims to replace the damaged section with a lab-grown spinal cord that fuses with healthy tissue above and below the injury. Animal studies in rats have shown remarkable results, with the animals regaining the ability to walk innovation began about three years ago, when Dvir's lab engineered a personalised three-dimensional human spinal cord in the laboratory. The findings, published in the peer-reviewed journal Advanced Science, showed that mice with chronic paralysis regained mobility after receiving the engineered procedure begins with blood cells from the patient, which are reprogrammed into stem-cell-like cells capable of becoming any cell type. Fat tissue is also collected to create a custom hydrogel scaffold, into which the stem-like cells develop into a spinal cord structure. This engineered tissue is then implanted, replacing scarred areas and reconnecting the nervous system.A few months ago, Prof. Dvir and his team received preliminary approval from Israel's Ministry of Health for 'compassionate use" trials in eight patients, making Israel the first country to attempt this procedure. 'This is undoubtedly a matter of national pride. The technology was developed here in Israel, at Tel Aviv University and at Matricelf, and from the very beginning it was clear to us that the first-ever surgery would be performed in Israel, with an Israeli patient," Dvir technology was then commercialised through Matricelf, which was founded in 2019 under a licensing agreement with Tel Aviv University's technology transfer company, Ramot.'This milestone marks the shift from pioneering research to patient treatment. Using each patient's own cells eliminates key safety risks and positions Matricelf at the forefront of regenerative medicine. This first procedure is more than a scientific breakthrough; it is a step toward transforming an area of medicine long considered untreatable," said Matricelf CEO Gil added, 'If successful, this therapy could define a new standard of care in spinal cord repair, addressing a multi-billion-dollar market with no effective solutions today. We are proud that Israel is leading this global effort and are fully committed to bringing this innovation to patients worldwide."'Our goal is to help paralysed patients rise from their wheelchairs. The animal model trials showed extraordinary success, and we are hopeful that the results in humans will be just as promising," Dvir said. (ANI/TPS)
Time of India
4 hours ago
- Time of India
New COVID variant Stratus (XFG) spreads in the US: Symptoms, risks, and what you need to know
As the United States experiences another wave of COVID-19, a variant named Stratus (XFG) has caught the attention of health authorities. Officially identified as XFG, this recombinant strain was first detected in Southeast Asia in January 2025. While initially flying under the radar in the US, XFG accounted for 14% of all cases by late June, making it the third most prevalent variant according to the Centers for Disease Control and Prevention (CDC). Globally, the World Health Organization ( WHO ) has added XFG to its monitoring list, though it continues to classify the variant's overall public health risk as low. Experts reassure that current COVID-19 vaccines remain effective against symptomatic and severe disease caused by this strain. What is the new covid variant in the US Stratus (XFG) and how is it different XFG is a recombinant variant, meaning it combines genetic material from two earlier strains: F.7 and LP.8.1.2. While LP.8.1.2 is now the second most common strain in the US, XFG is notable for its mutations that may help it evade the immune system. Importantly, experts emphasize that these mutations do not make XFG more dangerous. According to Dr. Subhash Verma, microbiology and immunology professor at the University of Nevada, XFG does not cause more severe illness or different symptoms compared to earlier Omicron variants. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Use an AI Writing Tool That Actually Understands Your Voice Grammarly Install Now Undo Health authorities classify the variant as low risk, but continued monitoring is essential to track its evolution. How fast is this covid variant As reported by USA Today, XFG's prevalence in the US has increased rapidly in recent months: March 2025: 0% of cases April 2025: 2% of cases May 2025: 6% of cases Late June 2025: 14% of cases Globally, the WHO reported a rise from 7.4% in early May to 22.7% by the end of June across 38 countries. Despite this growth, XFG has not surpassed the top two variants, but its upward trend underscores the importance of ongoing genomic surveillance and vaccine coverage. Symptoms of Stratus (XFG) variant As USA Today reported, know the familiar COVID-19 symptoms for XFG infections. These include: Fever or chills Cough Fatigue Sore throat Loss of taste or smell Nasal congestion Muscle aches Shortness of breath Headache Nausea or vomiting Health officials stress that symptom patterns remain consistent with prior Omicron variants, and early testing, vaccination, and isolation are key to controlling spread. Prevention tips for Stratus (XFG) variant To reduce the risk of infection from the XFG variant (Stratus), follow these recommended safety measures: Stay up to date with COVID-19 vaccines: Ensure primary doses and booster shots are current, as vaccines remain effective against severe disease. Practice good hygiene: Regular handwashing, using hand sanitizer, and avoiding touching the face can reduce transmission. Wear masks in crowded or enclosed spaces: Especially in public transport, healthcare facilities, or areas with high case counts. Maintain physical distancing: Avoid close contact with people showing respiratory symptoms. Monitor symptoms and test early: Get tested if you experience fever, cough, fatigue, or other COVID-related symptoms. Isolate if infected: Follow local health guidelines to prevent spreading the virus to others. Ventilate indoor spaces: Increase airflow in homes, offices, and public spaces to reduce viral concentration. Disclaimer : The information provided in this article is for general educational purposes only and is based on data available from the reputable news sources as of August 2025. It should not be considered medical advice. Always consult healthcare professionals for personal guidance on COVID-19 prevention, testing, and treatment. Also read | Sudden cardiac arrest in gyms: Causes, prevention tips, and urgent advisory issued for young athletes by Punjab government
Indian Express
4 hours ago
- Indian Express
ICMR study flags unregulated herbal tobacco products on e-commerce sites
A new study has found that herbal cigarettes, often marketed as 'safer alternatives,' produce harmful combustion products that are similar to those found in tobacco cigarettes. The affordability and digital accessibility of these products, combined with misleading health claims, pose significant risks to tobacco users seeking genuine cessation support, said researchers from Indian Council of Medical Research (ICMR)-National Institute of Cancer Prevention and Research. Dr Prashant Kumar Singh, lead author and scientist, ICMR-National Institute of Cancer Prevention and Research, said that their study, published in the journal Tobacco Control, found at least 316 unverified herbal products targeting tobacco users across major Indian e-commerce platforms. 'Herbal tobacco cessation products (HTCPs), marketed with claims to support tobacco or nicotine cessation, are increasingly sold online in low and middle-income countries. However, there is little regulatory oversight or evidence on their safety and effectiveness. This study assessed the availability, affordability, claims and regulation of HTCPs on Indian e-commerce platforms,' Dr Singh told The Indian Express. In India, as per the report, there are approximately 266.8 million users of tobacco, the majority of whom consume smokeless tobacco products. Despite substantial progress in tobacco control, the reach of cessation services remains uneven across different population groups. According to the study authors, recent studies indicate that HTCPs are increasingly being used by young adults and the regulatory landscape for these products remains fragmented. HTCPs encompass a broad category of formulations—including herbal capsules, lozenges, gutkha substitutes, powders and herbal smokes—claimed as natural, safer alternatives to conventional pharmacotherapy. According to Dr Singh, these products are increasingly available on digital platforms, where vendors often make therapeutic claims such as 'eliminates cravings,' 'detoxifies lungs,' or 'replaces gutkha safely'. Researchers searched some of the major Indian e-commerce platforms, screened product listings and categorised product type, claimed indications, presence of disclaimers, regulatory approvals and pricing. 'We were able to identify 316 unique HTCPs across some of the major Indian e-commerce platforms,' he said. The study showed that HTCPs were marketed in three primary formulations: combustible products (42.7 per cent), raw herbal preparations (34.5 per cent) and other formats such as gummies, drops, capsules and patches (22.8 per cent). Products featured diverse flavours and varied widely in pricing. 'Our verification of regulatory claims through official databases adds credibility to the findings,' Dr Singh said. According to the study findings, only 23 per cent of products with AYUSH claims and 15 per cent with Central Drugs Standard Control Organisation (CDSCO) claims could be verified through official databases. Of the 316 HTCPs, 197 (62.3 per cent) reported at least one form of certification claim. Additionally, 43.7 per cent of products promoted ancillary health claims such as detoxification or anxiety relief. Only 12 of the products displayed age restrictions, and none had functional age verification mechanisms. A small fraction (0.5 per cent) referenced World Health Organization (WHO) affiliation, raising concerns about potentially misleading endorsements. The authors urged e-commerce platforms to implement mandatory health claims verification and functional age-restriction protocols. They added that all products must undergo testing in accredited facilities, such as the National Tobacco Testing Laboratories.
